0E

Uniqure NVLSE Uniqure Stock Report

Last reporting period 30 Sep, 2024

Updated 02 Dec, 2024

Last price

Market cap $B

0.25

Micro

Exchange

XLON - London Stock Exchange

0EE0.L Stock Analysis

0E

Uncovered

Uniqure NV is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-50/100

Low score

Market cap $B

0.25

Dividend yield

Shares outstanding

46.983 B

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 501 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

View Section: Eyestock Rating